Question · asked by 1 review
Any systemic treatment vs placebo: Tofacitinib
- Population
- people with chronic plaque psoriasis
- Intervention
- Any systemic treatment
- Comparison
- placebo
- Outcome
- Tofacitinib
Any systemic treatment may leads to higher tofacitinib compared with placebo (low certainty).
What each review found
Current versions onlyNo studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 2 · 66.7%Moderate 1 · 33.3%High 0 · 0%
| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Any systemic treatment vs placebo Tofacitinib · people with chronic plaque psoriasis Any systemic treatment may leads to higher tofacitinib compared with placebo (low certainty). Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis (2020) · Cochrane Headline outcomes only | RR 8.19 [6.53, 10.29] | 5 studies · 3092 participants | Low |
Any systemic treatment vs placebo Tofacitinib · people with chronic plaque psoriasis Any systemic treatment showed no clear difference in tofacitinib compared with placebo (moderate certainty). Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis (2020) · Cochrane Headline outcomes only | RR 1.01 [0.57, 1.77] | 7 studies · 3122 participants | Moderate |
Any systemic treatment vs placebo Tofacitinib · people with chronic plaque psoriasis Any systemic treatment may leads to higher tofacitinib compared with placebo (low certainty). Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis (2017) · Cochrane Headline outcomes onlyearlier version CD011535.PUB2, superseded | RR 8.5 [6.23, 11.6] | 4 studies · 2826 participants | Low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis 2020 · Cochrane Headline outcomes only | Not reported | Not extracted | Not assessed |
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.